Chrysoula Pipili
Overview
Explore the profile of Chrysoula Pipili including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
252
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Albert C, Zapf A, Haase M, Rover C, Pickering J, Albert A, et al.
Am J Kidney Dis
. 2020 Jul;
76(6):826-841.e1.
PMID: 32679151
Rationale & Objective: The usefulness of measures of neutrophil gelatinase-associated lipocalin (NGAL) in urine or plasma obtained on clinical laboratory platforms for predicting acute kidney injury (AKI) and AKI requiring...
2.
Cholongitas E, Koukoufiki A, Pipili C, Antoniadis N, Fouzas I, Haidich A, et al.
Indian J Gastroenterol
. 2019 Sep;
38(4):348-355.
PMID: 31515763
Background: As the mortality rates after liver transplantation (LT) have been reduced, the attention has shifted to additional conditions which still compromise the quality of life and the survival of...
3.
Pipili C, Kiosses D, Hatzigeorgiou-Sandberg G
Saudi J Kidney Dis Transpl
. 2018 Feb;
29(1):217-220.
PMID: 29456235
No abstract available.
4.
Cholongitas E, Goulis I, Pagkalidou E, Haidich A, Karagiannis A, Nakouti T, et al.
Ann Hepatol
. 2017 Jun;
16(4):584-590.
PMID: 28611262
Background: The clinical impact of relative adrenal insufficiency (AI) on patients with stable decompensated cirrhosis (DeCi) has not been yet elucidated. Aim: Explore the association between AI and outcome [death...
5.
Cholongitas E, Pipili C, Papatheodoridis G
World J Hepatol
. 2017 Feb;
9(4):180-190.
PMID: 28217256
Treatment of patients with chronic kidney disease (CKD) and chronic hepatitis C (CHC) differs from that used in the general CHC population mostly when glomerular filtration rate (GFR) is below...
6.
Grapsa E, Pipili C, Angelopoulos E, Pantelias K, Kapetanaki A, Deda E, et al.
Minerva Urol Nefrol
. 2016 Feb;
68(1):20-6.
PMID: 26856608
Background: The establishment of accurate equations for glomerular filtration rate (GFR) estimations is still far from the realization. Factors such as age, diabetes, stage of CKD, pregnancy, muscle mass and...
7.
Pipili C, Cholongitas E
World J Gastrointest Pharmacol Ther
. 2015 Nov;
6(4):105-10.
PMID: 26558143
The combination of hepatitis B immune globulin with entecavir or tenofovir (at least for a certain period of time) seems to be the most reasonable prophylaxis against recurrent hepatitis B...
8.
Pipili C, Vasileiadis I, Grapsa E, Tripodaki E, Ioannidou S, Papastylianou A, et al.
Microvasc Res
. 2015 Oct;
103:14-8.
PMID: 26431994
Objective: The purpose of this study was to evaluate microcirculation over 24 h renal replacement therapy (CRRT) in critically ill patients. Methods: We conducted a single-center, prospective, observational study, measuring...
9.
Cholongitas E, Pipili C, Papatheodoridis G
World J Gastroenterol
. 2015 Sep;
21(32):9526-33.
PMID: 26327760
The goal of therapy in chronic hepatitis C virus (HCV) infection is sustained virological response (SVR) which reflects HCV eradication. Treatment against HCV has dramatically improved with the recent availability...
10.
Pipili C, Cholongitas E
World J Hepatol
. 2015 Jul;
7(12):1606-16.
PMID: 26140081
The first generation direct antiviral agents (DAAs) highlighted substantial prognosis improvement among liver transplant (LT) candidates and recipients with recurrent hepatitis C virus (HCV) infection. During 2014, second generation DAAs...